Security National Bank Boosts Stock Position in Zoetis Inc. (NYSE:ZTS)

Security National Bank raised its position in shares of Zoetis Inc. (NYSE:ZTS) by 2.4% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 51,448 shares of the company’s stock after acquiring an additional 1,184 shares during the period. Zoetis makes up approximately 2.5% of Security National Bank’s holdings, making the stock its 9th largest holding. Security National Bank’s holdings in Zoetis were worth $9,988,000 as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Amundi bought a new stake in shares of Zoetis in the 2nd quarter worth approximately $321,789,000. Macquarie Group Ltd. boosted its position in shares of Zoetis by 641.7% in the 2nd quarter. Macquarie Group Ltd. now owns 1,465,375 shares of the company’s stock worth $273,087,000 after purchasing an additional 1,267,799 shares in the last quarter. Lord Abbett & CO. LLC boosted its position in shares of Zoetis by 387.5% in the 2nd quarter. Lord Abbett & CO. LLC now owns 1,417,899 shares of the company’s stock worth $264,240,000 after purchasing an additional 1,127,067 shares in the last quarter. 1832 Asset Management L.P. boosted its position in shares of Zoetis by 697.9% in the 2nd quarter. 1832 Asset Management L.P. now owns 1,225,267 shares of the company’s stock worth $229,952,000 after purchasing an additional 1,071,708 shares in the last quarter. Finally, AKO Capital LLP boosted its position in shares of Zoetis by 52.9% in the 2nd quarter. AKO Capital LLP now owns 2,432,203 shares of the company’s stock worth $453,265,000 after purchasing an additional 841,224 shares in the last quarter. 89.48% of the stock is currently owned by institutional investors and hedge funds.

ZTS has been the topic of a number of analyst reports. Barclays boosted their price target on Zoetis from $235.00 to $240.00 and gave the stock an “overweight” rating in a research report on Friday, November 5th. They noted that the move was a valuation call. Morgan Stanley initiated coverage on Zoetis in a research report on Thursday, November 18th. They issued an “overweight” rating and a $264.00 price target on the stock. Credit Suisse Group boosted their price target on Zoetis from $206.00 to $230.00 and gave the stock an “outperform” rating in a research report on Monday, August 9th. Finally, Argus boosted their price objective on shares of Zoetis from $195.00 to $225.00 and gave the stock a “buy” rating in a report on Wednesday, August 25th. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Buy” and an average target price of $212.30.

NYSE ZTS traded down $0.49 during mid-day trading on Thursday, reaching $223.17. The stock had a trading volume of 1,177,948 shares, compared to its average volume of 1,727,186. The stock has a market cap of $105.59 billion, a PE ratio of 53.78, a price-to-earnings-growth ratio of 3.33 and a beta of 0.66. The company has a debt-to-equity ratio of 1.41, a current ratio of 4.54 and a quick ratio of 3.27. The company has a fifty day moving average price of $207.89 and a 200 day moving average price of $197.91. Zoetis Inc. has a 1 year low of $141.41 and a 1 year high of $228.89.

Zoetis (NYSE:ZTS) last announced its earnings results on Thursday, November 4th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.10 by $0.15. The business had revenue of $1.99 billion during the quarter, compared to analyst estimates of $1.93 billion. Zoetis had a net margin of 26.02% and a return on equity of 52.17%. The company’s quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.10 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 4.64 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, December 1st. Shareholders of record on Friday, October 29th will be paid a dividend of $0.25 per share. The ex-dividend date is Thursday, October 28th. This represents a $1.00 dividend on an annualized basis and a yield of 0.45%. Zoetis’s dividend payout ratio is presently 24.10%.

In other news, EVP Roxanne Lagano sold 1,315 shares of the business’s stock in a transaction on Thursday, September 23rd. The shares were sold at an average price of $202.17, for a total transaction of $265,853.55. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Heidi C. Chen sold 9,446 shares of the business’s stock in a transaction on Monday, October 25th. The shares were sold at an average price of $210.22, for a total transaction of $1,985,738.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 31,834 shares of company stock valued at $6,741,997. Company insiders own 0.17% of the company’s stock.

About Zoetis

Zoetis, Inc discovers, develops, and manufactures a portfolio of animal health medicines and vaccines. The firm operates through the following segments: United States &International. Its products are complemented by diagnostic products, genetic tests, bio devices, and services. These are designed to meet the needs of veterinarians and the livestock farmers and companion animal.

Recommended Story: Calculating net profit and net profit margin ratio

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.